Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
by Share, Size, Revenue, Top Manufacturers and Forecast

A new Report by Delvens, titled "Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Market” offers a comprehensive analysis of the
industry, which comprises insights on the Global analysis. The report also
includes competitor and regional analysis, and contemporary advancements in the
market, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market size
was estimated at USD 7,820 million in 2023 and is projected to reach USD
13,753.5 million in 2030 at a CAGR of 8.40% during the forecast period to 2030.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is
a rare, progressive autoimmune disorder characterized by the inflammation of
peripheral nerves, leading to demyelination, motor weakness, sensory loss, and
in some cases, severe disability. It is considered the most common type of
chronic acquired neuropathy and affects both adults and children.

Get Free Sample
Report: https://www.delvens.com/get-free-sample/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
market is driven by increasing awareness, advancements in diagnostic tools, and
the growing adoption of targeted treatments such as immunoglobulin therapies
and biologics. CIDP, a rare autoimmune disorder causing progressive nerve
damage, is becoming more diagnosable as healthcare systems improve globally,
expanding the potential market for treatments.

Key trends include the shift towards precision medicine and
personalized therapies, fuelled by genetic and biomarker research. The market
is also supported by rising autoimmune disease prevalence and ongoing drug
development, although challenges such as high treatment costs and limited healthcare
access in certain regions may impact growth. As better treatments and earlier
diagnosis emerge, the CIDP market is expected to continue expanding in the
coming years.

North America to
Dominate the Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Market

North America led the global Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) Market in 2021, capturing over 44.90% of
the total revenue. The region's growth is expected to continue, driven by the
approval and launch of new immunotherapy treatments and favourable
reimbursement policies. For example, in October 2021, Merck’s Keytruda, an
anti-PD-1 therapy, received FDA approval in combination with chemotherapy for
cervical cancer.

Additionally, in August 2021, Bristol Myers Squibb's OPDIVO
(nivolumab) was approved by the FDA for treating urothelial carcinoma.

Recent Developments

In June 2022, Bio
Products Laboratory (BPL) obtained marketing authorization for Congaed in the
Dominican Republic, a key milestone in the treatment of Hereditary Factor X
Deficiency.

In February 2022, Grifols
partnered with Endpoint Health, Inc. to develop an Antithrombin III (AT-III)
therapy for Sepsis.

Furthermore, in
January 2022, Janssen Pharmaceutical teamed up with SRI International to
utilize SRI's SynFin platform in small molecule drug discovery, aiming to
advance research into complex neurological disorders, including CIDP.

The Prominent Players
in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

·       
F. Hoffmann-La Roche Ltd.

·       
Mylan N.V.

·       
Teva Pharmaceutical Industries Ltd.

·       
Sanofi

·       
Pfizer Inc.

·       
GSK plc

·       
Novartis AG

·       
AstraZeneca

·       
Johnson & Johnson Private Limited

·       
Sun Pharmaceutical Industries Ltd.

·       
Merck & Co., Inc.

·       
Lilly

·       
Amgen Inc.

·       
Actelion Pharmaceuticals Ltd. and More

Access Full Report: https://www.delvens.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

In addition to the
market data for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Market, Delvens offers client-centric reports customized according to the
company’s specific demand and requirements.

Frequently Asked
Questions

·       
What are the years considered to study Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) Market intelligence report?

·       
What is the compound annual growth rate (CAGR)
of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

·       
Which region holds the largest market share in
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

·       
Which region is the fastest growing in Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

·       
Who are the major players in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Market?

About Us:

Delvens is a strategic advisory and consulting company
headquartered in New Delhi, India. The company holds expertise in providing
syndicated research reports, customized research reports and consulting
services. Delvens qualitative and quantitative data is highly utilized by each
level from niche to major markets, serving more than 1K prominent companies by assuring
to provide the information on country, regional and global business
environment. We have a database for more than 45 industries in more than 115+
major countries globally.

Delvens database assists the clients by providing in-depth
information in crucial business decisions. Delvens offers significant facts and
figures across various industries namely Healthcare, IT & Telecom,
Chemicals & Materials, Semiconductor & Electronics, Energy,
Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company
provides an exhaustive and comprehensive understanding of the business
environment.

Contact us:

Unit No. 01, 3rd Floor, Plot No. 56, Block B

Sector 2 Noida, Near Noida Sector 15 Metro Station 201301,
IN

+44 20 3290 6466

+0120- 4903958

sales@delvens.com